TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22706940

Group type: EXPERIMENTAL
Intervention: FLIRT (First Line Intermittent Recompression Technique)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (Buehlmann‐based decompression profile)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: FLIRT
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 19896325

Group type: EXPERIMENTAL
Intervention: Photon stimulation
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 17966969

Group type: EXPERIMENTAL
Intervention: Metformin (M, n = 13)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gliclazide (G, n = 13)
Number of subjects: 26
Study: 16310013

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0
Study: 12761365

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-protein, high-fat diet
Number of subjects: 63
Study: 12383809

Group type: EXPERIMENTAL
Intervention: Frequency-doubling technology glaucoma screening protocol (FDT-GSP)
Number of subjects: 14817
Study: 10402259

Group type: EXPERIMENTAL
Intervention: Intense but task-irrelevant 'accessory' stimulus accompanying the imperative stimulus in a choice reaction task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Condition with three alternative responses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel dependent measure introduced: latency of spontaneous, post-trial blinking
Number of subjects: 0
Study: 7480274

Group type: EXPERIMENTAL
Intervention: Betamethasone 6 mg IM preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: No steroid treatment
Number of subjects: 50
Study: 2381618

Group type: EXPERIMENTAL
Intervention: 0.8% terconazole cream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.6% terconazole cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7030835

Group type: EXPERIMENTAL
Intervention: CDCA (12‐15 mg/kg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: UDCA (5‐6 mg/kg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: UDCA (10‐12 mg/kg/day)
Number of subjects: 116
Study: 31888729

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: One-anastomosis gastric bypass (OAGB)
Number of subjects: 120
Study: 28342637

Group type: EXPERIMENTAL
Intervention: Rituximab plus short-term prednisone (1000 mg IV on days 0 and 14, 500 mg at months 12 and 18; prednisone 0.5 or 1.0 mg/kg per day tapered over 3 or 6 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prednisone alone (1.0 or 1.5 mg/kg per day tapered over 12 or 18 months)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Rituximab plus short-term prednisone
Number of subjects: 90
Study: 26073163

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 175
Study: 23374963

Group type: EXPERIMENTAL
Intervention: Thoracodorsal nerve divided during reconstruction (group 1)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Thoracodorsal nerve preserved during reconstruction (group 2)
Number of subjects: 29
Study: 21601366

Group type: EXPERIMENTAL
Intervention: Dexamethasone treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Baseline conditions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fear-potentiated startle (FPS)
Number of subjects: 100
Study: 19119169

Group type: EXPERIMENTAL
Intervention: Refrigerant (1,1,1,3,3‐pentafluoropropane/1,1,1,2‐tetrafluoroethane) applied for 5 seconds
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical anesthetic gel (20 percent benzocaine gel) applied for 2 minutes
Number of subjects: 16
Study: 17483861

Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with ILM peeling
Number of subjects: 11
Study: 15155717

Group type: EXPERIMENTAL
Intervention: 6% CHO solution before and during training and 20% solution post-exercise (H-CHO trial)
Number of subjects: 6

Group type: COMPARATOR
Intervention: 2% CHO solution before and during training and 2% solution post-exercise (L-CHO trial)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: H-CHO trial
Number of subjects: 6

Group type: COMPARATOR
Intervention: L-CHO trial
Number of subjects: 6
Study: 11439734

Group type: EXPERIMENTAL
Intervention: Rofecoxib (5 to 50 mg)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672
Study: 9603669

Group type: EXPERIMENTAL
Intervention: Topically applied 1% beta‐LHA formulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7522547

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 100
Study: 3403064

Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-carotene (180 mg/week) plus vitamin A (100,000 IU/week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31663369

Group type: EXPERIMENTAL
Intervention: Preoperative progressive resistance training (PRT) for 4 weeks followed by postoperative PRT for 4 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (lived as usual for 4 weeks before TKA, followed by 4 weeks postoperative PRT)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Preoperative progressive resistance training (PRT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 29402370

Group type: EXPERIMENTAL
Intervention: Permissive underfeeding
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard enteral feeding
Number of subjects: 82
Study: 26613819

Group type: EXPERIMENTAL
Intervention: 400 μg misoprostol with 10 units of oxytocin
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo with 10 units of oxytocin
Number of subjects: 288
Study: 24914476

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 20
Study: 22512515

Group type: EXPERIMENTAL
Intervention: Provox Vega
Number of subjects: 31

Group type: COMPARATOR
Intervention: Blom-Singer Classic Indwelling
Number of subjects: 31
Study: 20547039

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 54
Study: 18452345

Group type: EXPERIMENTAL
Intervention: Quetiapine 300 mg/day
Number of subjects: 694

Group type: EXPERIMENTAL
Intervention: Quetiapine 600 mg/day
Number of subjects: 694

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 694
Study: 16167707

Group type: EXPERIMENTAL
Intervention: Daily iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (60 mg tablet containing 300 microg ferrous sulphate and 400 microg folic acid for three months)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (not supplemented)
Number of subjects: 207
Study: 15083762

Group type: EXPERIMENTAL
Intervention: Nasal mask (NM)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Full face mask (FFM)
Number of subjects: 16
Study: 11039133

Group type: EXPERIMENTAL
Intervention: Natural surfactant
Number of subjects: 24

Group type: COMPARATOR
Intervention: Synthetic surfactant
Number of subjects: 24
Study: 9372401

Group type: EXPERIMENTAL
Intervention: Physical training course
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group (no training course)
Number of subjects: 151
Study: 1590012

Group type: EXPERIMENTAL
Intervention: Ossiplex retard
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mono-Tridin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ossin
Number of subjects: 12
Study: 2863185

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Clemastine
Number of subjects: 30
Study: 3219882

Group type: EXPERIMENTAL
Intervention: 2 mg pinaverium bromide intravenously
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 4 mg pinaverium bromide intravenously
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31933461

Group type: EXPERIMENTAL
Intervention: Community-based water intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to intervention uptake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enablers to intervention uptake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to health reporting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enablers to health reporting
Number of subjects: 0
Study: 30849015

Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS) with PermaCem Dual Smartmix (PER) and tribochemical silica coating (TBC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Immediate Dentin Sealing (IDS) with Panavia F2.0 (PAN) and tribochemical silica coating (TBC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS) with PermaCem Dual Smartmix (PER) and airborne particle abrasion (APA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Delayed Dentin Sealing (DDS) with Panavia F2.0 (PAN) and airborne particle abrasion (APA)
Number of subjects: 60
Study: 28613996

Group type: EXPERIMENTAL
Intervention: Greater personal resilience resources (composite variable of self-esteem, mastery, and optimism)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Greater personal resilience resources
Number of subjects: 254
Study: 25640830

Group type: EXPERIMENTAL
Intervention: PROSPER intervention
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Maternal involvement
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: DRD4 variation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serotonin transporter linked polymorphic region (5-HTTLPR)
Number of subjects: 28
Study: 23775505

Group type: EXPERIMENTAL
Intervention: Remifentanil at steady-state effect-site concentrations of 0, 1.2, 1.8, 2.4, 3, 3.6, 4.8, and 6 ng/ml
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Combination of three surrogate parameters (pupil diameter, light reflex amplitude, and tracking performance)
Number of subjects: 16
Study: 21569011

Group type: EXPERIMENTAL
Intervention: Context therapy
Number of subjects: 0
Study: 19505910

Group type: COMPARATOR
Intervention: HPV-16 infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV-6 or -11
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPV-16
Number of subjects: 0
Study: 16800900

Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whole-brain radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 11919130

Group type: EXPERIMENTAL
Intervention: 2 x NPH daily
Number of subjects: 104

Group type: COMPARATOR
Intervention: 1 x NPH
Number of subjects: 104
Study: 10503820

Group type: EXPERIMENTAL
Intervention: Long-term acid inhibition therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term acid-inhibitory therapy for an average of three years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term acid inhibition in individuals with H. pylori infection
Number of subjects: 0
Study: 7751706

Group type: EXPERIMENTAL
Intervention: Atovaquone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 0
Study: 2260008

Group type: EXPERIMENTAL
Intervention: Hypoxyradiotherapy with a mixture of nitrogen and oxygen containing 8.0 to 8.5% O2, increased external irradiation doses by 40%
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional radiotherapeutic procedure
Number of subjects: 120
Study: 31816508

Group type: EXPERIMENTAL
Intervention: Online social support groups
Number of subjects: 0
Study: 29943097

Group type: EXPERIMENTAL
Intervention: Sensorimotor exercises
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Moderate strength training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 36
Study: 26838252

Group type: EXPERIMENTAL
Intervention: Information leaflet intervention given to the intervention group of 280 participants.
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group of 220 participants who did not receive the information leaflet.
Number of subjects: 500
Study: 25166480

Group type: EXPERIMENTAL
Intervention: Ecopipam (50 to 100 mg/d as needed)
Number of subjects: 28
Study: 22940562

Group type: EXPERIMENTAL
Intervention: Prescribed opioid dose
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Patient-reported opioid dose
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Opioid deviation
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Barriers Questionnaire-II (BQ-II) scores
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Adherence scores
Number of subjects: 198
Study: 21073712

Group type: EXPERIMENTAL
Intervention: Usual GP care plus facilitated physical activity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual GP care
Number of subjects: 0
Study: 17953954

Group type: EXPERIMENTAL
Intervention: Suturing of the ovary (Group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Bipolar coagulation (Group B)
Number of subjects: 32
Study: 17181890

Group type: EXPERIMENTAL
Intervention: Dairy group (DG: n 39) receiving approximately 1200 mg calcium/d and 7.5 microg vitamin D3/d through fortified dairy products
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Calcium-supplemented group (CaG: n 26) provided with a calcium supplement of 600 mg/d
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (CG: n 36)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Dairy group (DG)
Number of subjects: 101
Study: 14523483

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stent implantation and GP IIb/IIIa receptor inhibitors in patients with NSTEACS (group A)
Number of subjects: 479

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) in patients with stable angina (group B)
Number of subjects: 479
Study: 10813102

Group type: EXPERIMENTAL
Intervention: Lovelle (desogestrel 0.15 mg plus ethinyl estradiol 0.02 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Valette (dienogest 2.0 mg plus ethinyl estradiol 0.03 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Lovelle
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both contraceptives
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Valette
Number of subjects: 31
Study: 8785183

Group type: EXPERIMENTAL
Intervention: Oxymetholone monotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oxymetholone plus ketotifen
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both treatment groups (Oxymetholone monotherapy and Oxymetholone plus ketotifen)
Number of subjects: 30
Study: 1830313

Group type: EXPERIMENTAL
Intervention: Furosemide (Lasix Retard)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiazide (hydrochlorthiazide)
Number of subjects: 24
Study: 7091039

Group type: EXPERIMENTAL
Intervention: EG AA group, 3 eggs + 2 g ascorbic acid
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EGGS group, 3 eggs + placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: AA group, 2 g ascorbic acid
Number of subjects: 40

Group type: COMPARATOR
Intervention: CONTROL group, placebo only
Number of subjects: 40
Study: 31912490

Group type: EXPERIMENTAL
Intervention: Community-based couple therapy
Number of subjects: 3347
Study: 31517749

Group type: EXPERIMENTAL
Intervention: Perturbation treadmill training (PTT)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional treadmill training (CTT)
Number of subjects: 43
Study: 28928001

Group type: EXPERIMENTAL
Intervention: Drone-snowmobile Technique (DST)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classical Line Search Technique (CLT)
Number of subjects: 20
Study: 27669288

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (6000 IU daily for 12 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo supplement (for those with vitamin D status over 75 nmol/L)
Number of subjects: 20
Study: 24731234

Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care (MTFC)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Group care (GC) treatment as usual (TAU)
Number of subjects: 166
Study: 22092038

Group type: EXPERIMENTAL
Intervention: Doxycycline (28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21115589

Group type: COMPARATOR
Intervention: B vitamins (5‐methyltetrahydrofolate 560 μg, vitamin B‐6 3 mg, vitamin B‐12 20 μg)
Number of subjects: 2501

Group type: COMPARATOR
Intervention: Omega 3 fatty acids (600 mg of eicosapentanoic acid and docosahexaenoic acid at a ratio of 2:1)
Number of subjects: 2501
Study: 18784373

Group type: EXPERIMENTAL
Intervention: Tocilizumab (anti-IL-6 receptor antibody)
Number of subjects: 0
Study: 16005273

Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin (sCT) 1.0 mg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Oral salmon calcitonin (sCT) (0.15, 0.4, 1.0, or 2.5 mg)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 12925107

Group type: EXPERIMENTAL
Intervention: Trovafloxacin + Cefepime
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trovafloxacin + Amikacin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefepime alone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Trovafloxacin alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefepime + Trovafloxacin
Number of subjects: 12
Study: 10095141

Group type: EXPERIMENTAL
Intervention: 2 ml 50% sucrose solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2 ml sterile water (placebo)
Number of subjects: 100
Study: 8608096

Group type: EXPERIMENTAL
Intervention: Low dose aspirin (60 mg)
Number of subjects: 1009

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1009
Study: 1317687

Group type: EXPERIMENTAL
Intervention: Lisinopril (mean dose 35 mg qd)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nifedipine (mean dose 54 mg bid)
Number of subjects: 21
Study: 6485438

Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Secretin (1 CU/kg/h, 0 to 120 min.) + GIH-CCK (1 IU/kg/h, 60 to 120 min.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaCl infusion (control)
Number of subjects: 20
Study: 30267667

Group type: EXPERIMENTAL
Intervention: Isolated core postural control training with an unstable seat apparatus
Number of subjects: 33

Group type: COMPARATOR
Intervention: Physiotherapy exercises (stretching and strengthening)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Isolated core postural control training
Number of subjects: 33
Study: 30879460

Group type: EXPERIMENTAL
Intervention: Pronator sparing plate osteosynthesis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-sparing approach
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 26601738

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 1307

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 1307
Study: 23104956

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 21
Study: 23157083

Group type: EXPERIMENTAL
Intervention: Local instillation of 0.75% ropivacaine (20 ml)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Fentanyl and flurbiprofen
Number of subjects: 29
Study: 19592206

Group type: EXPERIMENTAL
Intervention: Epoetin alfa (20,000 IU, 10 daily doses starting from the day of trauma)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 19017587

Group type: EXPERIMENTAL
Intervention: 4 months of daily rifampin therapy
Number of subjects: 847

Group type: COMPARATOR
Intervention: 9 months of daily isoniazid therapy
Number of subjects: 847
Study: 15747247

Group type: EXPERIMENTAL
Intervention: 1x10(5) TCID(50) bPIV3 vaccine
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 1x10(6) TCID(50) bPIV3 vaccine
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 12451727

Group type: EXPERIMENTAL
Intervention: Ribavirin 1200 mg daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10600085

Group type: EXPERIMENTAL
Intervention: Multidisciplinary antimicrobial treatment team intervention
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 252
Study: 7875277

Group type: EXPERIMENTAL
Intervention: Hygroscopic condenser humidifier
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no protection system)
Number of subjects: 40
Study: 3047886

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29305400

Group type: EXPERIMENTAL
Intervention: Catheter ablation in amio-refractory patients
Number of subjects: 259

Group type: COMPARATOR
Intervention: Escalated drug therapy in amio-refractory patients
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Catheter ablation in sotalol-refractory patients
Number of subjects: 259

Group type: COMPARATOR
Intervention: Escalated drug therapy in sotalol-refractory patients
Number of subjects: 259
Study: 28083797

Group type: EXPERIMENTAL
Intervention: Oral fludrocortisone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of oral fludrocortisone and intravenous hydrocortisone
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 24929799

Group type: EXPERIMENTAL
Intervention: PHARMACOP-intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22245630

Group type: EXPERIMENTAL
Intervention: Saracatinib 50 mg/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Saracatinib 125 mg/day
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Saracatinib 175 mg/day
Number of subjects: 51
Study: 20186300

Group type: EXPERIMENTAL
Intervention: Auditory training
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no auditory training)
Number of subjects: 14